MondayJul 15, 2024 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Replicate Results from First GLP-1 Study Following CRO Contract Award for 12-Week Chronic Human Study

Lexaria, a global innovator in drug delivery platforms, recently hired a contract research organization (“CRO”) for its upcoming chronic human study, GLP-1-H24-4 This study will seek to evaluate various glucagon-like peptide-1 (“GLP-1”) formulations, processed with the company’s patented DehydraTECH(TM) technology The study will feature five arms, with each conducted using several investigational sites in Australia Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the hiring of a contract research organization (“CRO”) that will be responsible for overseeing the execution of the company’s upcoming chronic human study, GLP-1-H24-4. This 12-week study will seek to evaluate various…

Continue Reading

MondayJun 24, 2024 12:45 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Second Round of Dosing for Human Pilot Study #2; Set to Complete Third Study Arm in Early July

Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration The study’s main objective is to evaluate Lexaria’s patented DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug, semaglutide, currently commercially available as Rybelsus(R) The commencement of the pilot study shows Lexaria’s commitment to its promise to focus on GLP-1 studies for 2024, along with its confidence in its…

Continue Reading

MondayJun 17, 2024 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires CRO; Set for First Tirzepatide Molecule Study

Lexaria, a global innovator in drug delivery platforms, recently announced the hiring of a Contract Research Organization (“CRO”) for its third human pilot study The study, a randomized, crossover investigation, will evaluate a dual-action glucagon-like peptide 1 (“GLP-1”) + glucose-dependent insulintropic peptide (“GIP”) It will measure absorption, tolerability, pharmacokinetics, and blood sugar levels Lexaria is counting on its patented DehydraTECH technology for significant growth in the 2024 calendar year, and the study reflects this commitment Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the hiring of a Contract Research Organization (“CRO”) for its third human…

Continue Reading

FridayJun 14, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Neurodegenerative Diseases

INM is advancing INM-089 targeting age-related macular degeneration and INM-901 targeting Alzheimer’s disease The company recently posted positive results for INM-089 demonstrating significant functional and pathological improvements in an AMD disease model Recent preclinical data for INM-901 displayed positive pharmacological effects for treating Alzheimer's disease INM posted a business update for Q3-2024 reporting a closing cash position of US$7.9 million and revenue growth for subsidiary BayMedica, a supplier of rare cannabinoids as ingredients InMed Pharmaceuticals (NASDAQ: INM), a is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s…

Continue Reading

ThursdayJun 13, 2024 9:00 am

Mullen Automotive Inc. (NASDAQ: MULN) Subsidiary Announces First Dealership Deal in Market Projected to See Record Sales

Bloomberg analyst projects 2024 EV sales in the U.S. at nearly 2 million units, making up 13% of new-car purchases Mullen subsidiary inks first commercial dealership agreement with LaFontaine Automotive Group Bollinger Motors expects to start delivering the Bollinger B4 later this year While some headlines in the past few months make it seem like the electric vehicle market is in trouble, a recent “Car and Driver” article forecasts that EV sales are just getting started. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, appears to support that projection, with the recent announcement that its subsidiary, Bollinger Motors, has entered a distribution…

Continue Reading

MondayJun 10, 2024 12:00 pm

GEMXX Corp. (GEMZ) Announces Definitive Agreement with Latin Energy Partners in Strategic Latin America Venture

The strategic venture marks a milestone in the company’s expansion into the energy sector, demonstrating GEMXX’s commitment to diversification and growth The project will be overseen by Dinesh Kumar Sarraf, the former chairman and managing director of Oil and Natural Gas Corporation Ltd, India's leading exploration and production company The drilling of the four test wells is set to begin in the coming months, with expected results providing valuable data on the region's oil potential GEMXX (OTC: GEMZ), a publicly traded exploration company engaged in gold, gemstones, oil, and gas, has announced the signing of a Definitive Agreement with Latin…

Continue Reading

MondayJun 10, 2024 9:45 am

Mullen Automotive Inc. (NASDAQ: MULN) Class 3 EV Truck Receives CARB Certification, Joins Class 1 EV Van in Meeting Stringent Emission Standards

CARB certification is awarded to vehicle manufacturers that meet specific emissions standards in compliance with CARB regulations CARB is charged with protecting public from harmful effects of air pollution, developing programs and actions to fight climate change “Having both our Class 1 and Class 3 commercial EVs now CARB and EPA certified will continue to drive sales in all states across America,” says Mullen CEO With environmental concerns becoming an increasing priority, more states, companies, and consumers are paying attention to — and prioritizing — environmentally friendly products and practices. Mullen Automotive (NASDAQ: MULN), an emerging EV manufacturer, shares this commitment to being…

Continue Reading

ThursdayJun 06, 2024 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24 The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships Lexaria Bioscience (NASDAQ: LEXX),…

Continue Reading

FridayMay 31, 2024 9:45 am

GEMXX Corp. (GEMZ) Enters Alliance with Latin Energy Partners to Advance Groundbreaking Developments in Oil Exploration in Latin America

GEMXX recently entered a significant partnership with Latin Energy Partners that has seen the two companies define terms to jointly drill four test wells in a promising geologic formation in a Latin American country The partnership is part of GEMXX’s plans to strategically expand its current successful business model, diversifying its business portfolio, and exploring new underground resource opportunities Latin America has large tracts and regions of under-explored sedimentary basins which hold significant oil and gas resources potential Preliminary explorations in the two basins suggest potential for more than 1 billion barrels each of recoverable oil, positioning GEMXX and Latin…

Continue Reading

TuesdayMay 28, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Concludes First Dosing for its Second GLP-1 Human Pilot Study; Maintains Study Pace and Rollout for 2024

Lexaria, a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 GLP-1, a class of drugs, has demonstrated the ability to address diabetes and weight loss, albeit with poor oral bioavailability, usually as little as 0.8% Lexaria, through its study, looks to demonstrate the effectiveness of its DehydraTECH(TM) technology in improving GLP-1’s bioavailability, opening up a vast worldwide market Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just concluded its first dosing for its glucagon-peptide-1 (“GLP-1”) human pilot study #2, GLP-1-H24-2 ( This follows the recent…

Continue Reading

Contact us: (310) 299-1717